AusTrials is pleased to have been involved in conducting the ARISE-HF Phase 3 trial which has since announced encouraging results. Applied Therapeutics, a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, has announced the topline results of the ARISE-HF Phase 3…
Associate Professor Roy Rasalam has joined the new AusTrials site in Melbourne as the Principal Investigator. He is a clinician researcher and has a special interest in diabetes clinical care and research and co-author of the Diabetes Australia & RACGP type 2 diabetes national guidelines. Roy brings over 25 years of clinical experience from both…
Diabetes mellitus (DM) is an increasingly common, yet complex and chronic metabolic illness that requires ongoing medical care. Type 2 DM (T2DM) is the most common form of DM, resulting from an interaction of genetic, environmental, and behavioural factors. Within 20 years, the number of people in Australia with T2DM may increase from an estimated 870,000 in 2014, to more than 2.5 million. People with diabetes…
